American Shared Hospital Services (AMS)
XASE:AMS
Want to see AMS full AI Analyst Report?
Top Page
American Shared Hospital Services
(NYSE MKT:AMS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▼(-28.57% Downside)
Action:ReiteratedDate:05/02/26
The score is held down primarily by weak financial performance—margin compression, a return to losses, and sustained negative free cash flow with liquidity/covenant pressure. Technicals are mixed (short-term improvement but longer-term downtrend). Valuation remains unattractive/unclear due to losses and no dividend support, while the earnings call adds some offset from improving volumes and expansion plans but is constrained by going-concern and lender-negotiation risk.
Positive Factors
Direct patient care revenue growth
A durable shift toward direct patient care (now the majority of revenue) creates more usage‑based, recurring cash flows and less reliance on leasing cycles. As volume scales, per‑procedure economics and revenue predictability should improve, supporting sustainable margin recovery and reinvestment.
Negative Factors
Material gross margin compression
A sharp, sustained drop in gross margin materially reduces profit per treatment and weakens the firm's ability to fund operations and capex from internal cash. If driven by structural pricing pressure or higher operating costs, margin recovery will take months and constrain free cash flow and reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Direct patient care revenue growth
A durable shift toward direct patient care (now the majority of revenue) creates more usage‑based, recurring cash flows and less reliance on leasing cycles. As volume scales, per‑procedure economics and revenue predictability should improve, supporting sustainable margin recovery and reinvestment.
Read all positive factors
American Shared Hospital Services (AMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.22M
Dividend YieldN/A
Average Volume (3M)78.93K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth-0.91%
EPS Growth-168.54%
CountryUS
Employees81
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.23
Shares Outstanding6,602,000
10 Day Avg. Volume41,017
30 Day Avg. Volume78,931
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.58
Price to Sales (P/S)0.50
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.79
Enterprise Value/Revenue1.11
Enterprise Value/Gross Profit6.18
Enterprise Value/Ebitda7.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
American Shared Hospital Services Business Overview & Revenue Model
Company Description
American Shared Hospital Services (AMS) is a leading provider of advanced medical equipment and services to healthcare facilities across the United States. The company specializes in offering cutting-edge technologies in the field of radiation the...
How the Company Makes Money
AMS makes money primarily by providing hospitals with access to expensive, specialized medical technology through shared-services and similar arrangements, rather than hospitals purchasing and operating all equipment entirely on their own. Under t...
American Shared Hospital Services Earnings Call Summary
Earnings Call Date:Mar 31, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The call described meaningful operational progress—growth in direct patient care, strong LINAC volume expansion, international gains, partnership extensions and stabilized clinical staffing—positioning the company for future growth. However, these positives are counterbalanced by significant near-term financial stress: compressed gross margins, a full-year net loss versus prior-year income, a large decline in cash balance, unmet covenant metrics, and a stated going-concern risk that requires lender amendments. Management is optimistic about the long-term trajectory, but the company's liquidity and covenant issues represent material short-term risks.Positive Updates
Direct Patient Care Revenue Growth
Direct Patient Care Services revenue increased 23.7% year-over-year to $15.5M for FY2025 and comprised 63% of Q4 revenue ($4.8M), reflecting the successful shift to a direct patient care model and more stable, scalable revenue mix.
Negative Updates
Quarterly and Leasing Revenue Declines
Q4 total revenue declined 14.8% to $7.7M (from $9.1M), driven by lower proton beam volumes and the expiration of three Gamma Knife contracts; Medical Equipment Leasing revenue fell 33.9% in Q4 to $2.9M and leasing revenue declined for the year to $12.6M.
Read all updates
Q4-2025 Updates
Positive
Negative
Direct Patient Care Revenue Growth
Direct Patient Care Services revenue increased 23.7% year-over-year to $15.5M for FY2025 and comprised 63% of Q4 revenue ($4.8M), reflecting the successful shift to a direct patient care model and more stable, scalable revenue mix.
Read all positive updates
Company Guidance
Management's guidance was cautiously optimistic: they expect 2026 to show improving treatment volumes and margins as the company scales its now majority direct‑patient care platform (FY 2025 revenue $28.1M; direct patient care revenue +23.7% to $15.5M; leasing $12.6M), pointing to strong LINAC momentum (LINAC revenue +35.4% to $11.5M and 28,147 LINAC sessions in 2025) and early same‑center volume gains into 2026; they reiterated priorities to increase volumes, drive operational efficiencies and margin improvement (FY gross margin $5.1M/18%; Q4 gross margin 12%; FY adjusted EBITDA $5.5M; Q4 adj. EBITDA $868K). Key growth catalysts and timing include Guadalajara beginning operations in 2026, a Bristol center targeted late‑2027 and a proton center in 2028 with staffing begun several months before openings, a 7‑year Orlando Health lease extension, and ongoing lender negotiations to amend covenants and secure flexibility given year‑end cash of ~$3.7M, total debt of ~$17.3M, $7.5M of 2025 capex, and shareholders' equity of $24M ($3.66/sh).American Shared Hospital Services Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
58
Neutral
Cash Flow
39
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.08M | 28.34M | 21.32M | 19.75M | 17.63M |
| Gross Profit | 5.06M | 9.19M | 9.34M | 8.38M | 6.73M |
| EBITDA | 4.07M | 8.91M | 6.97M | 8.44M | 6.97M |
| Net Income | -1.55M | 2.19M | 610.00K | 1.33M | 194.00K |
Balance Sheet | |||||
| Total Assets | 55.48M | 60.20M | 48.16M | 43.96M | 45.43M |
| Cash, Cash Equivalents and Short-Term Investments | 3.46M | 11.03M | 13.69M | 12.34M | 8.14M |
| Total Debt | 22.61M | 23.23M | 17.64M | 14.31M | 17.47M |
| Total Liabilities | 27.79M | 30.17M | 21.88M | 18.33M | 21.19M |
| Stockholders Equity | 24.03M | 25.18M | 22.62M | 21.63M | 19.89M |
Cash Flow | |||||
| Free Cash Flow | -4.54B | -7.77M | -555.00K | 6.85M | 4.59M |
| Operating Cash Flow | 3.10B | 167.00K | 5.72M | 7.24M | 6.27M |
| Investing Cash Flow | -7.63B | -7.11M | -6.27M | -388.00K | -1.67M |
| Financing Cash Flow | -3.03B | 4.41M | 1.91M | -2.66M | -655.00K |
American Shared Hospital Services Technical Analysis
Neutral
2.10
Price Trends
1.90
Negative
2.01
Negative
2.22
Negative
Market Momentum
-0.16
Negative
46.68
Neutral
55.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMS, the sentiment is Neutral. The current price of 2.1 is above the 20-day moving average (MA) of 1.56, above the 50-day MA of 1.90, and below the 200-day MA of 2.22, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 46.68 is Neutral, neither overbought nor oversold. The STOCH value of 55.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMS.
American Shared Hospital Services Risk Analysis
American Shared Hospital Services disclosed 20 risk factors in its most recent earnings report. American Shared Hospital Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
American Shared Hospital Services Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $66.62M | -0.16 | -71.45% | ― | -47.74% | -1056.93% | |
48 Neutral | $11.22M | -5.59 | -8.75% | ― | -0.91% | -168.54% | |
46 Neutral | $28.19M | 145.34 | 15.82% | 11.14% | -2.56% | -2181.76% | |
45 Neutral | $17.15M | -0.11 | ― | ― | 20.26% | 69.68% | |
45 Neutral | $21.14M | -0.08 | -257.39% | ― | -2.76% | -1.22% |
* Healthcare Sector Average
AMS
American Shared Hospital Services
1.70
-0.98
-36.57%
CCM
Concord Medical Services
3.95
-2.80
-41.48%
CCEL
Cryo-Cell International
3.50
-1.24
-26.14%
DCGO
DocGo
0.67
-1.68
-71.32%
PIII
P3 Health Partners
2.93
-5.86
-66.67%
American Shared Hospital Services Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
American Shared Hospital Services Names Craig Tagawa Interim CEO
Neutral
Apr 24, 2026
On April 20, 2026, American Shared Hospital Services announced that Chief Executive Officer Gary Delanois resigned for personal reasons, effective April 24, 2026, marking a leadership change at the healthcare services provider. On April 23, 2026, ...
Business Operations and Strategy
American Shared Hospital Extends Proton Therapy Lease Agreement
Positive
Mar 19, 2026
American Shared Hospital Services has amended its long-standing Proton Beam Radiation Therapy Lease Agreement with Orlando Health, originally executed in 2006 and previously modified in 2012. On March 13, 2026, the parties agreed to extend the lea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.